Phytoestrogens for osteoporosis

Clinical Reviews in Bone and Mineral Metabolism

Volumn 2, Issue 4, 2004, Pages 341-356

  Button, Brenna J ^a   Patel, Nima ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

Coumestans; Ipriflavone; Isoflavones; Lignans; Osteoporosis; Phytoestrogens; Soy

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; CORTICOSTEROID; DIURETIC AGENT; DOCETAXEL; DOXORUBICIN; ESTRADIOL PLUS NORETHISTERONE ACETATE; FEMARELLE; GENISTEIN; GLYCOSIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; IPRIFLAVONE; ISOFLAVONE; ISOFLAVONE DERIVATIVE; LIGNAN; ORAL CONTRACEPTIVE AGENT; PHYTOESTROGEN; PROTON PUMP INHIBITOR; TAMOXIFEN; THEOPHYLLINE; TOFUPILL; UNCLASSIFIED DRUG;

ALFALFA; ALLERGIC REACTION; ANAPHYLAXIS; BLOATING; BONE DENSITY; BONE MINERAL; BONE TURNOVER; BREAST CANCER; BURNING SENSATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG USE; EPIGASTRIC PAIN; FLATULENCE; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GLYCYRRHIZA; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; LETHARGY; LIBIDO DISORDER; LINSEED; LYMPHOCYTOPENIA; MENOPAUSAL SYNDROME; MYALGIA; NAUSEA; OSTEOPOROSIS; PANCYTOPENIA; PATIENT EDUCATION; PATIENT SELECTION; PHOTOSENSITIVITY; PRURITUS; PSEUDOHYPOALDOSTERONISM; RED CLOVER; REVIEW; SKIN DISEASE; SOYBEAN; SPOTTING;

EID: 27544472851     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/BMM:2:4:341     Document Type: Review

References (81)

1. Magruder LA. 1999 Obstacles to the use of estrogen replacement therapy of lower socioeconomic levels. J Am Board Fam Pract 12(2):154-157.
2. Rossouw JE, Anderson GL, Prentice RL, et al. 2002 Writing Group for the Women's. risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled. JAMA 288(3):321-333.
3. Anderson GL, Limacher M, Assaf AR, et al. 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291(14):1701-1712.
4. Hersh AL, Stefanick ML, Stafford RS. 2004 National use of postmenopausal hormone therapy. JAMA 291(1):47-53.
5. Blumenthal M. Summer. 2000 Herb sales down 3% in mass market retail stores-sales in natural food stores still growing, but at lower rate. Herbalgam 49:68.
6. 2002 Top Selling U.S. Herbs 1997-2001. Nutrition Business Journal Available at: http://www.nutritionbusiness.com/sub/charts/topherbs.xls. [Accessed. July 27, 2004].
7. U.S. Food and Drug Administration Website. http://www.fda.gov/opacom/ laws/dshea.html [accessed February 26, 2004].
8. Mills S, Bone K. 2000 Principles and Practice of Phytotherapy. Modern Herbal Medicine, 1st ed., Churchill Livingstone, New York.
9. Fitzpatrick LA. 2003 Phytoestrogens-mechanism of action and effect on bone markers and bone mineral density. Endocrinol Metab Clin N Am 32:233-252.
10. Kurzer M, Xu X. 1997 Dietary phytoestrogens. Ann Rev Nutr 17:353-381.
11. Kuiper GGJM, Lemmen J, Carlsson BO, et al. 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptorß. Endocrinology 139(10):4252-4263.
12. Notoya K, Yoshida K, Tsukuda R, Taketomi S. 1993 Inhibitory effects of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cells. Calcif Tissue Int 53:206-209.
13. Chen SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R. 1994 Stimulation of human osteoblast differentiation and function by ipriflavvone and its metabolites. Calcif Tissue Int 55:356-362.
14. USDA-Iowa State University Isoflavones Database. http://www.nal.usda.gov/ fnic/foodcomp/Data/isoflav/isoflav.html [accessed March 28, 2004].
15. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. 1997 Expression of estrogen receptor β in rat bone. Endocrinology 138:4509-4512.
16. Kuiper GGJM, Carlsson BO, Grandien K, et al. 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870.
17. 2000 Consensus Opinion of The North American Menopause Society. The role of isoflavones in menopausal health. Menopause 7:215-229.
18. Setchell K, Lydeking-Olsen E. 2003 dietary phytoestrogens and their effect on bone: Evidence from in vitro and in vivo, human observational, and dietary intervention Studies. Am JClin Nutr 78(suppl):593S-609S.
19. Barnes S. 2003 Phytoestrogens and osteoporosis: What is a safe dose? Br J Nutr 89(suppl 1):S101-S108.
20. Mei J, Yeung S, Kung A. 2001 High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 86(11):5217-5221.
21. Potter SM, Baum JA, Hongyu T, Stillman RJ, Shay NF, Erdman Jr JW. 1998 Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68(suppl1):1375S-9S.
22. Uesugi T, Fukui Y, Yamori Y. 2002 Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: A four-week study. J Am Coll Nutr 21(2):97-102.
23. Chen Y, Ho SL, Lam SSH, Ho SSS, Woo JLF. 2003 Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: A double-blind, randomized, controlled trial. J Clin Endocrinol Metab 88(10):4740-4747.
24. Yamori Y, Moriguchi EH, Teramoto T, et al. 2002 Soybean isoflavones reduce postmenopausal bone resorption in female Japanese immigrants in Brazil: A Ten-Week Study. J Am Coll Nutr 21(6):560-563.
25. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ. 2003 The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrino 58:704-709.
26. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. 2002 Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am JClin Nutr 71:844-852.
27. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. 2004 The effects of phytoestrogen isoflavones on bone density in women: A Double-blind, Randomized, Placebo-Controlled Trial. American Journal of Clinical Nutrition 79:326-33.
28. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. 2001 The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 8(4):259-265.
29. Knudson Schult TM, Ensrud KE, Blackwell T, Ettinger B, Wallace R, Tice JA. 2004 Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas 15;48(3):209-218
30. Morabito N, Crisafulli A, Vergara C, et al. 2002 Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: A randomized double-blind placebo-controlled study. J Bone Min Res 17(10):1904-1912.
31. Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B. 2003 Tofupill/Femarell (DT56a): A new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss. Menopause 10(6):522-525.
32. Arjmandi BH, Khalil DA, Smith BJ, et al. 2003 Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 88(3):1048-1054.
33. Anderson JJB, Chen X, Boass A, et al. 2002 Soy isoflavones: No effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year. J Am Coll Nutr 21(5):388-393.
34. Glazier MG, Bowman MA. 2001 A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch of Int Med 161(9):1161-1172.
35. Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S. 1999. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Hormone Res 51:178-183.
36. Gennari C, Adami S, Agnusdei D, et al. 1997 Effect of chronic treatment with epriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 61:S19-S22.
37. Alexandersen P, Toussaint A, Christiansen C, et al. 2001 Ipriflavone in the treatment of postmenopausal osteoporosis. A randomized controlled trial. JAMA. 285(11):1482-1488.
38. Agnusdei D, Gennari C, Bufalino L. 1995 Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. European Foundation for Osteoporosis 5:462-466.
39. Nozaki M, Hashimoto K, Inoue Y, Ogata R, Okuma A, Nakano H. 1998 Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. Intl J Gynecol Obst 62:69-75.
40. Kettler, DB. 2001 Can manipulation of the ratio of essential fatty acids slow the rate of postmenopausal bone loss? Alternative Medicine 61(1) 61-77.
41. Kruger MC, Coetzer H, de Winter R, van Papendorp DH. 1998 Calcium, gamma-linoleic acid, eicosapentainoic acid supplementation in osteoporosis. Aging (Milano) 10:385-394
42. Lucas EA, Wild JD, Hammond LJ, et al. 2002 Flaxseed improves lipid profile without altering bone markers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 87(4):1527-1532.
43. Tham DM, Gardner CD, Haskell WL. 1998 Clinical Review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. Review. J Clin Endocrinol Metab 83(7):2223-35.
44. Kurzer MS. 2003 Phytoestrogen supplement use by women. Review. J Nutr 133(6):1983S-1986S.
45. Van Patten CL, Olivotto IA, Chambers GK, et al. 2002 Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 20(6):1449-55.
46. Tice JA, Ettinger B, Ensrud K, et al. 2003 Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 290(2):207-14.
47. Food and Drug Administration. 1999 Food labeling: health claims; soy protein and coronary heart disease. Fed Regist 64:57700-57733.
48. Anderson JW, Johnstone BM, Cook-Newell ME. 1995 Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333(5):276-82.
49. Lu LJ, Tice JA, Bellino FL. 2001 Phytoestrogens and healthy aging: gaps in knowledge. A workshop report. Menopause 8(3):157-70.
50. Murkies Al, Wilcox G, and Davis SR. 1998 Clinical Review 92: Phytoestrogens. J Clin Endocrinol Metab 83:297-303.
51. Key TJ, Sharp GB, Appleby PN, et al. 1999 Soya foods and breast cancer risk: a prospective study in Hiroshima and Nagasaki, Japan. Br J Cancer 81(7):1248-56.
52. Wang TT, Sathyamoorthy N, Phang JM. 1996 Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 17(2):271-5.
53. Adlercreutz H. 1995 Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 103(Suppl 7):103-112.
54. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. 2002 Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 62(9):2474-7.
55. Schwartz JA, Liu G, and Brooks SC. 1998 Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochem Biophys Res Commun 253(1):38-43.
56. Hodgson SF, Watts N, Bilezikian JP, et al. 2003 Revised AACE 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocrine Practice 7(4):293-312.
57. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Canadian Medical Association Journal 167(10):S1-S34.
58. Harkness L. 2004 Soy and bone. Where do we stand? Orthop Nurs 23(1):12-17.
59. Setchell KD. 1998 Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Review. Am J Clin Nutr 68(Suppl 6):1333S-1346S.
60. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. 1995 The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med 208(1):40-3.
61. Messina MJ. 2002 Soy foods and soybean isoflavones and menopausal health. Nutr Clin Care 5(6):272-82.
62. Promensil® Clinical Monograph Information, Novogen Pharmaceuticals, http://www.promensil.com/ [accessed April 1, 2004].
63. Rimostil® Clinical Monograph Information, Novogen Pharmaceuticals, http://www.rimostil.com/ [accessed April 1, 2004].
64. Tofupill/Femarelle® Product Information, Se-cure Pharmaceuticals Ltd, http://www.tofupill.com/ [accessed April 1, 2004].
65. Ipriflavone® Drugdex Drug Evaluations. http://www.micromedex.com/ [accessed March 24, 2004].
66. Remifemin® Product Information, GlaxoSmithKline Pharmaceuticals, http://www.remifemin.com/ [accessed April 1, 2004].
67. CVS Online Pharmacy. http://www.cvs.com/. [accessed July 01, 2004]
68. Walgreens Online Pharmacy, http://www.walgreens.com/. [accessed July 01, 2004].
69. The Vitamin Shoppe. http://www.vitaminshoppe.com/. [accessed July 01, 2004].
70. 2001 Herbal Companion to American Hospital Formulary Service DI, 1st ed., Forget L, Goldrosen J, Hart JA, et al, eds., American Society of Health-System Pharmacists, Bethesda, Maryland.
71. 2003 Natural Medicines Comprehensive Database, 5th ed., Jellin JM, Gregory PJ, Scott GN., eds., Therapeutic Research Center, Stockton, California.
72. 2001 Physician's Desk Reference for Nutritional Supplement, 1st ed., Hendler SS Rorvik D., eds., Thomson Healthcare, Montvale, New Jersey.
73. Memorial Sloan-Kettering Cancer Center. Information Resource: About Herbs, Botanicals, & Other Products. http://www.mskcc.Org/mskcc/html/11570. cfm [accessed April 1, 2004].
74. Borrelli F, Izzo AA, Ernst E. 2003 Pharmacological effects of Cimicifuga racemosa. Life Sci 73:1215-1229.
75. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. 2002 Antiestrogenic activities of Cimicifuga racemosa extracts. J Steroid Biochem Mol Biol 80(1):125-130.
76. Kligler B. 2003 Black cohosh. Am Fam Phys Rev 68(1):114-116.
77. CL ConsumberLab.com® http://www.consumerlab.com/ [accessed April 1, 2004].
78. Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM. 2002 Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137:889-903.
79. Newall, CA, Anderson LA, Phillipson JD. 1996 Herbal Medicines: a Guide for Health-Care Professionals, 2nd ed., The Pharmaceutical Press, London, England.
80. Dennehy C, Tsourounis C. 2004 Herbs and Nutritional Supplements. In: Koda-Kimble MA, Young LY, Kradjan WA, eds.Applied therapeutics: the clinical use of drugs (8th ed.).Lippincott Williams & Wilkins, pp. 1-50.
81. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. 2004 Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 292(1):65-74.